Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 5/20 | 0.41 |
| ▸ | FPR3 | P25089 | 4/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118978 | 0.83 | GAA (0.59) | MCHR1NPC1RAB9ACNR1MEN1 | |
| SCHEMBL4126336 | 0.82 | CNR1 (0.50) | CNR1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4120234 | 0.78 | EPHX1 (0.53) | MCHR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL4112255 | 0.78 | POLB (0.52) | MCHR1NPC1RAB9ACNR1MEN1 | |
| SCHEMBL4115223 | 0.77 | FPR3 (0.46) | MCHR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL4119011 | 0.76 | MCHR1 (0.58) | MCHR1NPC1RAB9ACNR1MEN1 | |
| SCHEMBL4119645 | 0.76 | MCHR1 (0.60) | MCHR1CNR1MEN1KMT2AGAA | |
| SCHEMBL4118376 | 0.76 | MCHR1 (0.66) | MCHR1CNR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4125608 | 0.73 | MEN1 (0.61) | NPC1RAB9ACNR1MEN1KMT2A | |
| SCHEMBL4129057 | 0.72 | KMT2A (0.46) | MCHR1NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | claimed |
| EP-1711175-A1 | DIUREA DERIVATIVES | Active Biotech AB (SE) | 2006-10-18 | — | — | EP | claimed |
| WO-2005074919-A1 | DIUREA DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1711175-A1 | DIUREA DERIVATIVES | Active Biotech AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005074919-A1 | DIUREA DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | IL2, CASP2, MAVS | MCHR1 4128/4885NPC1 4607/4885RAB9A 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.